EVAL. OF HUMAN ANTICOLORECTAL CARCINOMA MOAB IN PATS. WITH DISSEM. COLON CA

大量患者接受了小鼠的治疗 几项I期和II期研究中的单抗。总体而言, 这种疗法的抗肿瘤效果令人失望。 一些。然而，已经证明抗体可以 到达肿瘤部位，并对肿瘤细胞进行特异性筛选。 一般说来，体内和外周血中的单抗 它们本身在当前使用时不是有效的工具 癌症的治疗。 使用鼠源性单抗的一个限制性特征 已经开发出了人类抗鼠抗体。如果 抗体最终被修饰成有效的 抗癌治疗对癌症患者的发展 人类抗鼠单抗仍将是一种重要的 有问题。因此，我们启动了一项使用人类单抗的研究 抗体在治疗结直肠癌患者中的尝试 癌症。两株人类单抗16.88和28A32 目前正在研究中。两者均来源于人类B细胞 来自结直肠癌患者的疫苗 自体肿瘤细胞疫苗。这些单抗具有 已被I-131放射性标记，并已定位于 转移性结直肠癌患者。在14名患者中 到目前为止，接受治疗的人中没有人产生抗体 注射人源单抗。然而，有两名患者 具有针对其中一个或两个的预先存在的抗体 单克隆抗体。这些患者没有进入 学习。尽管这些单抗被贩卖到 在荷瘤部位，未观察到抗肿瘤反应。

A large number of patients have been treated with murine monoclonal antibodies in several phase I and II studies. In general, the anti-tumor effects of this therapy have been disappointingly few. It has been demonstrated, however, that antibodies can reach the site of the tumor and strain the tumor cells specifically. In general it appears that monoclonal antibodies in and of themselves as currently being used are not effective tools in the treatment of cancer. One limiting feature of the use of murine monoclonal antibodies has been the development of human antimouse antibodies. If antibodies ultimately are modified to become an effective antitumor treatment for patients with cancer, the development of human antimouse monoclonal antibodies will still be a significant problem. We, therefore, initiated a study using human monoclonal antibodies in an attempt to treat patients with colorectal carcinoma. Two human monoclonal antibodies 16.88 and 28A32 are currently being studied. Both are derived from human B cells from patients with colorectal carcinoma immunized with an autologous tumor cell vaccine. These monoclonal antibodies have been radiolabeled with I-131 and have localized to tumors in patients with metastatic colorectal carcinoma. Of 14 patients treated so far, none have developed antibodies against the administered human monoclonal antibody. However, two patients had pre-existing antibody directed against either or both monoclonal antibodies. These patients were not entered on the study. Despite trafficking of these monoclonal antibodies to the tumor-bearing site, no antitumor responses have been observed.